Common Acne Drug, Benzoyl Peroxide, Might Become Carcinogenic at Room Temperature
By Dennis Thompson HealthDay Reporter
WEDNESDAY, Oct. 9, 2024 -- Widely-used acne creams can become contaminated with a known carcinogen even if kept at room temperature, a new study warns.
Creams containing benzoyl peroxide (BPO) can wind up containing high levels of benzene while sitting on a store shelf or in a medicine cabinet, researchers found after testing 111 products from major U.S. retailers.
Brands tested containing benzoyl peroxide included products from Clearasil, Clean & Clear, Neutrogena, Proactiv, Up & Up and store brand equivalents.
Benzoyl peroxide degrades into the carcinogen benzene over time when stored at room temperature, at elevated temperatures and when exposed to the ultraviolet rays of sunlight, researchers reported Oct. 7 in the Journal of Investigative Dermatology.
This is the first time that benzoyl peroxide products have been shown to degrade into benzene at normal temperatures, they noted.
“Our research demonstrates that BPO products can generate benzene at typical room and store shelf temperatures, while cold storage significantly reduces this formation,” said researcher Dr. Christopher Bunick, an associate professor of dermatology with the Yale University School of Medicine in New Haven, Conn.
The Environmental Protection Agency classifies benzene as a known human carcinogen, noting that it specifically increases the risk of leukemia.
Benzoyl peroxide acts as an antibacterial agent, and is found in over-the-counter remedies and prescription creams for acne and rosacea.
For the new study, researchers bought dozens of acne creams from major retail stores in California, Connecticut, Florida, Illinois, New York and Texas.
“The 111 BPO drug products tested from major U.S. retailers appear to be substantially contaminated with benzene when tested shortly after being acquired off the shelf,” they concluded.
About 34% of the products tested contained benzene concentrations above the U.S. Food and Drug Administration’s conditional limit of 2 parts per million for medications, results show.
However, there are no safe levels of exposure to benzene, researchers noted. The FDA says benzene has “unacceptable toxicity,” and its conditional limit is for “unavoidable” levels of benzene contained in drug products “with a significant therapeutic advance.”
The researchers’ testing revealed benzene concentrations in the products as high as 35.3 parts per million.
Testing also showed that refrigeration can slow benzoyl peroxide’s degradation into benzene, researchers said.
“These findings suggest a need to recommend refrigeration of BPO products throughout the supply chain -- from manufacturing to patient use-- to limit benzene exposure,” Bunick said in a journal news release. “Until formulations are developed to prevent benzene formation, refrigeration may serve as a practical solution to minimize unnecessary exposure.”
Dr. Richard Gallo, chair of dermatology with the University of California, San Diego, said that “this carefully done analysis should put to rest the question of whether benzene is present in skin care products that contain BPO.”
“It is now important that further studies be conducted to determine if the presence of this potential carcinogen in drugs with BPO translates into any increased risk of cancer,” added Gallo, who was not involved in the study.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-10 06:00
Read more
- Recommendations Updated on Diagnosis, Management of Premature/Primary Ovarian Insufficiency
- Don't Forget About Holiday Poisoning Pitfalls
- Meningitis Substantial Contributor to Mortality in Children Younger Than 5 Years
- Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura
- High Acceptance Seen for Liver Stiffness Test With Routine Retina Scan in T2DM
- Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions